News

Filter

Current filters:

Curis

1 to 9 of 11 results

Conditional EU approval for Roche basal cell carcinoma drug

15-07-2013

The European Commission has granted conditional approval to Swiss drug major Roche's (ROG: SIX) Erivedge…

BiotechnologyCurisErivedgeEuropeGenentechOncologyPharmaceuticalRegulationRoche

Curis in-licenses cancer candidate from Genentech

30-11-2012

US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss…

BiotechnologyCurisGDC-0917GenentechGUDC-427LicensingOncologyPharmaceuticalRoche

Faster-than-expected FDA approval of Roche’s vismodegib

31-01-2012

There was good news for Swiss drug major Roche's (ROG: SIX)subsidiary Genentech yesterday, when it received…

BiotechnologyCurisErivedgeGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

FDA priority review for Roche/Genentech’s vismodegib for skin cancer

10-11-2011

The US Food and Drug Administration has accepted and filed Swiss drug major Roche (ROG: SIX) subsidiary…

BiotechnologyCurisGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

Genentech files with US FDA for vismodegib in rare form of advanced skin cancer

13-09-2011

In a second filing for a novel skin cancer drug this year, Swiss drug major Roche (ROG: SIX) US subsidiary…

BiotechnologyCurisGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

Positive mid-stage data on Roche and Curis' BCC drug vismodegib

22-06-2011

Swiss drug major Roche (ROG: SIX) yesterday reported positive results from a mid-stage trial on vismodegib…

CurisOncologyPharmaceuticalResearchRochevismodegib

Strong Ph II results for Roche vismodegib in advanced basal cell carcinoma

22-03-2011

Swiss drug major Roche (SIX: ROG) said yesterday that a pivotal Phase II clinical study of its investigational…

CurisOncologyPharmaceuticalResearchRochevismodegob

1 to 9 of 11 results

Back to top